Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux, C.; Reid, D. M.; Devogelaer, J. P.et al.
2012 • In Osteoporosis International, 23, p. 1083-90
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis..pdf
[en] This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Zoledronic acid is significantly more effective than risedronate in increasing lumbar spine (LS) bone mineral density (BMD) in both prevention and treatment of glucocorticoid-induced osteoporosis. INTRODUCTION: In patients on glucocorticoids, a single zoledronic acid infusion significantly increased BMD versus daily oral risedronate. We assessed treatment effect on LS BMD in different patient subgroups at month 12 that contributed to the risk of osteoporosis in addition to glucocorticoids. METHODS: Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate (5 mg/day) and stratified based on glucocorticoids duration [treatment (>3 months) and prevention (</=3 months) subpopulations] were subgrouped by age; gender; menopausal status in women; dose and duration of prednisone during the trial; and baseline serum 25-OH vitamin D, LS BMD T-score, creatinine clearance, and concomitant medication use. RESULTS: At month 12, zoledronic acid significantly increased LS BMD versus risedronate in patients </=74 years (P < 0.05) in the treatment and 65-74 years (P = 0.0008) in the prevention subpopulation. At month 12, zoledronic acid significantly increased LS BMD versus risedronate in both subpopulations irrespective of gender (all P < 0.05), cumulative prednisone dose (all P < 0.01), and postmenopausal status (all P < 0.05). In premenopausal women, in both subpopulations, zoledronic acid significantly increased total hip BMD (all P < 0.05) versus risedronate at month 12 but not LS BMD. Osteoporotic patients in the prevention (P = 0.0189) and osteopenic patients in the treatment subpopulation (P = 0.0305) showed significant LS BMD increases with zoledronic acid versus risedronate at month 12. CONCLUSIONS: This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients.
Disciplines :
General & internal medicine
Author, co-author :
Roux, C.
Reid, D. M.
Devogelaer, J. P.
Saag, K.
Lau, C. S.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Papanastasiou, P.
Bucci-Rechtweg, C.
Su, G.
Sambrook, P. N.
Language :
English
Title :
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Publication date :
2012
Journal title :
Osteoporosis International
ISSN :
0937-941X
eISSN :
1433-2965
Publisher :
Springer Science & Business Media B.V., Godalming, United Kingdom
JP Devogelaer S Goemaere S Boonen JJ Body JM Kaufman JY Reginster S Rozenberg Y Boutsen 2006 Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club Osteoporos Int 17 8 19 16217586 1:CAS:528:DC%2BD2MXhtlWkt7rK 10.1007/s00198-005-2032-z (Pubitemid 41798023)
American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis 2001 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update Arthritis Rheum 2001 44 1496 1503 10.1002/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5 (Pubitemid 32642211)
L Caplan KG Saag 2009 Glucocorticoids and the risk of osteoporosis Expert Opin Drug Saf 8 33 47 19236216 1:CAS:528:DC%2BD1MXnsVWisg%3D%3D 10.1517/14740330802648194
PN Sambrook DR Hughes AE Nelson BG Robinson RS Mason 2003 Osteocyte viability with glucocorticoid treatment: relation to histomorphometry Ann Rheum Dis 62 1215 1217 14644862 1:STN:280:DC%2BD3srpsFGltA%3D%3D 10.1136/ard.2003. 008839 (Pubitemid 37500630)
S Benvenuti ML Brandi 2000 Corticosteroid-induced osteoporosis: pathogenesis and prevention Clin Exp Rheumatol 18 S64 S66 10948768 1:STN:280:DC%2BD3M%2FkvVGmtg%3D%3D
Roux C (2010) Osteoporosis in inflammatory joint diseases. Osteoporos Int. doi: 10.1007/s00198-010-1319-x
SL Silverman NE Lane 2009 Glucocorticoid-induced osteoporosis Curr Osteoporos Rep 7 23 26 19239826 10.1007/s11914-009-0005-4
PD Miller 2008 Anti-resorptives in the management of osteoporosis Best Pract Res Clin Endocrinol Metab 22 849 868 19028360 1:CAS:528:DC%2BD1cXhsVWmsbnK 10.1016/j.beem.2008.07.004
LI Plotkin SC Manolagas T Bellido 2006 Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs Bone 39 443 452 16627025 1:CAS:528:DC%2BD28XotFyksLg%3D 10.1016/j.bone.2006.02.060 (Pubitemid 44164640)
RG Russell NB Watts FH Ebetino MJ Rogers 2008 Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 733 759 18214569 1:CAS:528: DC%2BD1cXltFyjurw%3D 10.1007/s00198-007-0540-8
KG Saag R Emkey TJ Schnitzer JP Brown F Hawkins S Goemaere G Thamsborg UA Liberman PD Delmas MP Malice M Czachur AG Daifotis Glucocorticoid-Induced Osteoporosis Intervention Study Group 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis N Engl J Med 339 292 299 9682041 1:CAS:528:DyaK1cXlsVOitr4%3D 10.1056/NEJM199807303390502 (Pubitemid 28366417)
DM Reid RA Hughes RF Laan NA Sacco-Gibson DH Wenderoth S Adami RA Eusebio JP Devogelaer European Corticosteroid-Induced Osteoporosis Treatment Study 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial J Bone Miner Res 15 1006 1013 10841169 1:CAS:528:DC%2BD3cXktFKhtbs%3D 10.1359/jbmr.2000.15.6.1006 (Pubitemid 30350063)
S Cohen RM Levy M Keller E Boling RD Emkey M Greenwald TM Zizic S Wallach KL Sewell BP Lukert DW Axelrod AA Chines 1999 Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 42 2309 2318 10555025 1:CAS:528:DyaK1MXnvVShsLs%3D 10.1002/1529-0131(199911)42: 11<2309::AID-ANR8>3.0.CO;2-K (Pubitemid 30333410)
C Roux P Oriente R Laan RA Hughes J Ittner S Goemaere O Di Munno JM Pouillès S Horlait B Cortet Ciblos Study Group 1998 Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss J Clin Endocrinol Metab 83 1128 1133 9543129 1:CAS:528:DyaK1cXitlynsLc%3D 10.1210/jc.83.4.1128 (Pubitemid 28496380)
JD Adachi KG Saag PD Delmas UA Liberman RD Emkey E Seeman NE Lane JM Kaufman PE Poubelle F Hawkins R Correa-Rotter CJ Menkes JA Rodriguez-Portales TJ Schnitzer JA Block J Wing HH McIlwain R Westhovens J Brown JA Melo-Gomes BL Gruber MJ Yanover MO Leite KG Siminoski MC Nevitt JT Sharp MP Malice T Dumortier M Czachur W Carofano A Daifotis 2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial Arthritis Rheum 44 202 211 11212161 1:CAS:528:DC%2BD3MXht1yiu7o%3D 10.1002/1529-0131(200101)44: 1<202::AID-ANR27>3.0.CO;2-W (Pubitemid 32113136)
S Wallach S Cohen DM Reid RA Hughes DJ Hosking RF Laan SM Doherty M Maricic C Rosen J Brown I Barton AA Chines 2000 Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy Calcif Tissue Int 67 277 285 11000340 1:CAS:528:DC%2BD3cXntlOlu74%3D 10.1007/s002230001146
JTT Iwamoto Y Sato 2007 Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis-usefulness of alendronate and risedronate Expert Opin Pharmacother 8 2743 2756 17956196 1:CAS:528: DC%2BD2sXht1Siu7fN 10.1517/14656566.8.16.2743 (Pubitemid 350193714)
S Boonen D Vanderschueren K Venken K Milisen M Delforge P Haentjens 2008 Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance J Intern Med 264 315 332 18823505 1:CAS:528:DC%2BD1cXht1Omt7%2FK 10.1111/j.1365-2796.2008.02010.x
DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 17476007 1:CAS:528:DC%2BD2sXltVSktLc%3D 10.1056/NEJMoa067312 (Pubitemid 46698462)
KW Lyles CS Colón-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 17878149 1:CAS:528:DC%2BD2sXht1Kit7nN 10.1056/NEJMoa074941 (Pubitemid 350044800)
DM Reid JP Devogelaer K Saag C Roux CS Lau JY Reginster P Papanastasiou A Ferreira F Hartl T Fashola P Mesenbrink PN Sambrook 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 373 1253 1263 19362675 1:CAS:528:DC%2BD1MXktlyqtb4%3D 10.1016/S0140-6736(09)60250-6
SS Yeap DJ Hosking 2002 Management of corticosteroid-induced osteoporosis Rheumatology (Oxford) 41 1088 1094 1:CAS:528:DC%2BD38XovFOqtbY%3D 10.1093/rheumatology/41.10.1088 (Pubitemid 35203533)
DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 1244564 1:STN:280:DyaE28%2FnsF2isw%3D%3D 10.1159/000180580
TP Van Staa RF Laan IP Barton S Cohen DM Reid C Cooper 2003 Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy Arthritis Rheum 48 3224 3229 14613287 10.1002/art.11283 (Pubitemid 37409336)
V Naganathan G Jones P Nash G Nicholson J Eisman PN Sambrook 2000 Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use Arch Intern Med 160 2917 2922 11041898 1:STN:280:DC%2BD3crgt1Wlug%3D%3D 10.1001/archinte.160.19.2917 (Pubitemid 32009048)
SA Jamal VJ Swan JP Brown DA Hanley JC Prior A Papaioannou L Langsetmo RG Josse 2010 Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study Am J Kidney Dis 55 291 299 20042259 10.1053/j.ajkd.2009.10.049
M Tucci S Stucci S Strippoli F Silvestris 2010 Cytokine overproduction, T-cell activation, and defective T-regulatory functions promote nephritis in systemic lupus erythematosus J Biomed Biotechnol 2010 457146 20671931 10.1155/2010/457146
PG Pecora B Kaplan 1996 Corticosteroids and ulcers: is there an association? Ann Pharmacother 30 870 872 8826575 1:STN:280:DyaK28vitl2ktw%3D%3D (Pubitemid 26243939)
LE Targownik LM Lix CJ Metge HJ Prior S Leung WD Leslie 2008 Use of proton pump inhibitors and risk of osteoporosis-related fractures CMAJ 179 319 326 18695179 10.1503/cmaj.071330
C Roux K Briot L Gossec S Kolta T Blenk D Felsenberg DM Reid R Eastell CC Glüer 2009 Increase in vertebral fracture risk in postmenopausal women using omeprazole Calcif Tissue Int 84 13 19 19023510 1:CAS:528: DC%2BD1MXitlegsg%3D%3D 10.1007/s00223-008-9188-4
